BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37284743)

  • 21. circDENND4C, a novel serum marker for epithelial ovarian cancer, acts as a tumor suppressor by downregulating miR-200b/c.
    Liu S; Yuan L; Li J; Liu Y; Wang H; Ren X
    Ann Med; 2023 Dec; 55(1):908-919. PubMed ID: 36896567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the clinical significances of serum HE4 with CA125 in peritoneal tuberculosis and epithelial ovarian cancer.
    Zhang L; Chen Y; Liu W; Wang K
    Biomarkers; 2016; 21(2):168-72. PubMed ID: 26667154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.
    Ning L; Lang J; Wu L
    BMC Cancer; 2022 Jan; 22(1):6. PubMed ID: 34980005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
    PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Medicine (Baltimore); 2015 Dec; 94(52):e2402. PubMed ID: 26717395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
    Moore RG; Blackman A; Miller MC; Robison K; DiSilvestro PA; Eklund EE; Strongin R; Messerlian G
    Gynecol Oncol; 2019 Jul; 154(1):150-155. PubMed ID: 30992143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer.
    Chen WT; Gao X; Han XD; Zheng H; Guo L; Lu RQ
    Asian Pac J Cancer Prev; 2014; 15(1):101-5. PubMed ID: 24528007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of the risk of ovarian malignancy algorithm index in predicting the recurrence of epithelial ovarian cancer.
    Li R; Ma S; Zu Y; Wang F; Gao T; Yang Y; Guo H; Ha C
    Biomark Med; 2022 Oct; 16(14):1055-1066. PubMed ID: 36062577
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma.
    Midulla C; Manganaro L; Longo F; Viggiani V; Frati L; Granato T; Anastasi E
    Tumour Biol; 2012 Oct; 33(5):1291-8. PubMed ID: 22430259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Epididymis Protein 4 (HE4) and Cancer Antigen 125 (CA125) for Prediction of Optimal Primary Surgery in Non-Mucinous Epithelial Ovarian Cancer.
    Promchit K; Oranratanaphan S
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):281-286. PubMed ID: 38285795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
    Innao P; Pothisuwan M; Pengsa P
    Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.